Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study.
Open Access
- 1 July 1988
- journal article
- case report
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 51 (7) , 947-949
- https://doi.org/10.1136/jnnp.51.7.947
Abstract
Sequential measurements of brain glucose metabolism were carried out in a patient with Wilson's disease, before and after successful treatment with D-penicillamine. They demonstrate an evolution of regional metabolism consistent with clinical improvement. The first study showed marked hypometabolism in the putamen on both sides. The second analysis showed bilateral improvement, with predominant residual deficits in the right putamen, while clinical symptoms of striatal dysfunction persisted on the left side. This observation suggests that positron emission tomography is able to follow the neurological evolution in cases of Wilson's disease.Keywords
This publication has 10 references indexed in Scilit:
- Wilson's disease studied with FDG and positron emission tomographyNeurology, 1987
- The Use of Trientine in Preventing the Effects of Interrupting Penicillamine Therapy in Wilson's DiseaseNew England Journal of Medicine, 1987
- Management of Wilson's disease with zinc sulphateJournal of the Neurological Sciences, 1987
- Dynamic, Gated and High Resolution Imaging with the ECAT IIIIEEE Transactions on Nuclear Science, 1986
- Treatment of Wilson's DiseaseAnnals of Internal Medicine, 1983
- Oral Zinc Therapy for Wilson's DiseaseAnnals of Internal Medicine, 1983
- TREATMENT OF WILSON'S DISEASE WITH TRIENTINE (TRIETHYLENE TETRAMINE) DIHYDROCHLORIDEThe Lancet, 1982
- Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of methodAnnals of Neurology, 1979
- Prevention of Wilson's Disease in Asymptomatic PatientsNew England Journal of Medicine, 1968
- Penicillamine, a new oral therapy for Wilson's diseaseThe American Journal of Medicine, 1956